Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 1 (1)
P 4 (1)

Trial Status

Unknown2
Not Yet Recruiting1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07450872Recruiting

Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors

NCT07518654Phase 1Not Yet Recruiting

Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma

NCT02931942UnknownPrimary

Changing Over Time of Ascorbic Acid After Chemotherapy

NCT04636918Phase 4UnknownPrimary

Ikervis for DED Due to GVHD Post Allo-HSCT

Showing all 4 trials

Research Network

Activity Timeline